Search this Site
Terbinafine News
NexMed Announces Patient Dosing in Phase 3 Program for Anti-Fungal Product
NexMed, Inc., a developer of innovative transdermal treatments based on the NexACT® drug delivery technology, today announced that its collaborator, Novartis, has commenced dosing of patients in the Phase 3 clinical trials for...
Pharmacoeconomic assessment of ciclopirox topical solution, 8%, oral terbinafine, and oral itraconazole for onychomycosis
Most pharmacoeconomic data available for antifungal agents are based on US or European cost parameters. Similar data have not been reported in a Canadian health care system.
Terbinafine-induced hepatic failure requiring liver transplantation
Drug-induced liver disease accounts for about 50% of acute or subacute liver failure in the United States.
Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects
Objective. Paroxetine is believed to be a substrate of CYP2D6. However, no information was available indicating drug interaction between paroxetine and inhibitors of CYP2D6. The aim of this study was to examine the effects of...
Subacute cutaneous lupus erythematosus induced by terbinafine
BACKGROUND: The onset of subacute cutaneous lupus erythematosus (SCLE) may be associated with the administration of a variety of drugs. Terbinafine, an oral antifungal agent, which rarely causes cutaneous eruptions, has been...